iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors

GAINESVILLE, Fla, March 14, 2025 /PRNewswire/ -- iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, today announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi's capabilities in developing cutting-edge immunotherapies for solid tumors.

As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune's shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure ensures the seamless continuation of TargImmune's research into novel tumor-targeted RNA therapies while benefiting from iOncologi's expanded resources and strategic vision.

"This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumors," said Dr. Edgardo Rodriguez-Lebron, iOncologi's recently appointed CEO. "TargImmune's pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options."

The acquisition aligns with iOncologi's broader strategy to expand its therapeutic pipeline, leverage next-generation RNA-based immunotherapies, and drive innovation in oncology.

About iOncologi, Inc.

iOncologi, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for the treatment of solid tumors. The company focuses on harnessing the power of the immune system to create next-generation oncology treatments that improve patient outcomes. For more information about iOncologi, Inc. and its ongoing efforts in immuno-oncology, please visit www.ioncologi.com or contact Dr. Edgardo Rodriguez-Lebron at [emailprotected].

About TargImmune Therapeutics

TargImmune Therapeutics is a biotechnology company developing targeted immunotherapy solutions designed to enhance anti-tumor immune responses. Headquartered in Basel, Switzerland, the company has pioneered novel approaches to advancing cancer treatment through innovative technologies. For more information about TargImmune Therapeutics please visit www.targimmune.com.

SOURCE iOncologi, Inc.